- Report
- March 2025
- 200 Pages
Global
From €4031EUR$4,490USD£3,433GBP
- Report
- April 2025
- 186 Pages
Global
From €4040EUR$4,500USD£3,441GBP
- Report
- January 2025
- 180 Pages
Global
From €3434EUR$3,825USD£2,925GBP
€4040EUR$4,500USD£3,441GBP
- Report
- January 2025
- 250 Pages
Global
From €4488EUR$4,999USD£3,822GBP
- Report
- May 2025
- 150 Pages
Global
From €2423EUR$2,699USD£2,064GBP
- Report
- May 2025
- 150 Pages
Global
From €2423EUR$2,699USD£2,064GBP
- Report
- May 2025
- 150 Pages
Global
From €2423EUR$2,699USD£2,064GBP
- Report
- May 2025
- 150 Pages
Global
From €2423EUR$2,699USD£2,064GBP
- Report
- May 2025
- 150 Pages
Global
From €2423EUR$2,699USD£2,064GBP
- Report
- May 2025
- 150 Pages
Global
From €2423EUR$2,699USD£2,064GBP
- Drug Pipelines
- April 2025
- 50 Pages
Global
From €1347EUR$1,500USD£1,147GBP
- Report
- December 2024
- 119 Pages
Global
From €3547EUR$3,950USD£3,020GBP
- Report
- November 2024
- 203 Pages
Global
From €3995EUR$4,450USD£3,402GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1347EUR$1,500USD£1,147GBP
- Clinical Trials
- April 2025
- 80 Pages
Global
From €1796EUR$2,000USD£1,529GBP
- Drug Pipelines
- April 2025
- 100 Pages
Global
From €1796EUR$2,000USD£1,529GBP
- Drug Pipelines
- April 2025
- 70 Pages
Global
From €1347EUR$1,500USD£1,147GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1347EUR$1,500USD£1,147GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1347EUR$1,500USD£1,147GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1122EUR$1,250USD£956GBP

The Antimicrobial Resistance (AMR) market is a subset of the healthcare services industry that focuses on the development of treatments and strategies to combat the growing threat of drug-resistant bacteria. AMR is a major public health concern, as it can lead to increased morbidity and mortality, as well as higher healthcare costs. To address this issue, the market is focused on developing new antibiotics, diagnostics, and vaccines, as well as strategies to reduce the spread of drug-resistant bacteria. Additionally, the market is focused on improving the stewardship of existing antibiotics, as well as developing new strategies to reduce the emergence of drug-resistant bacteria.
Some companies in the AMR market include Merck & Co., Pfizer, GlaxoSmithKline, Sanofi, Johnson & Johnson, Novartis, and AstraZeneca. Show Less Read more